Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.

Protein engineering, design & selection : PEDS - 1 Jan 2006

Erickson Heidi A, Jund Michelle D, Pennell Christopher A

Abstract excerpt

Immunotoxins are targeted therapeutics designed to kill cancer cells. The targeting moiety of an immunotoxin selectively binds to a tumor cell and targets it for death via an attached toxin. Because the toxins are typically of plant or bacterial origin, their clinical use is limited by immunogenicity and nonspecific toxicity. To circumvent these problems, we have begun to engineer immunotoxins containing human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Catalysis
Share to Cytosol
Share to Cytotoxicity, Immunologic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunoglobulin Variable Region

Share to Immunotoxins

Share to Leukemia, T-Cell

Share to Protein Synthesis Inhibitors

Share to Ribonucleases

Source

Identifiers

PMID: 16243897
DOI: 10.1093/protein/gzi073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytotoxicity of human RNase-based immunotoxins requires cytosolic access and resistance to ribonuclease inhibition.PMID 16243897Read ↗

Engineering Human Pancreatic RNase 1 as an Immunotherapeutic Agent for Cancer Therapy Through Computational and Experimental Studies.Semantic proximity Read ↗

Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo.Semantic proximity Read ↗

Generation of new cytotoxic human ribonuclease variants directed to the nucleus.Semantic proximity Read ↗

Engineering immunotoxin-equipped effector cells and evaluation in primary human immune cellsSemantic proximity Read ↗

Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential.Semantic proximity Read ↗

Rationally designed chemokine-based toxin targeting the viral G protein-coupled receptor US28 potently inhibits cytomegalovirus infection in vivoSemantic proximity Read ↗

Human antibody RNase fusion protein targeting CD30+ lymphomasSemantic proximity Read ↗

Characterization of prokaryotic recombinant Aspergillus ribotoxin alpha-sarcin.Semantic proximity Read ↗

Engineering of ovine pancreatic RNase A as an Anti-tumor agent through in silico and experimental approaches.Semantic proximity Read ↗

A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity.Semantic proximity Read ↗

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.Semantic proximity Read ↗

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.